We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now?
Read MoreHide Full Article
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
One stock to keep an eye on is Rigel Pharmaceuticals (RIGL - Free Report) . RIGL is currently holding a Zacks Rank #2 (Buy) and a Value grade of A.
Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. RIGL has a P/S ratio of 1.75. This compares to its industry's average P/S of 3.73.
Finally, we should also recognize that RIGL has a P/CF ratio of 9.33. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. RIGL's P/CF compares to its industry's average P/CF of 12.83. Over the past year, RIGL's P/CF has been as high as 96.38 and as low as -21.56, with a median of 10.07.
USANA Health Sciences (USNA - Free Report) may be another strong Medical - Drugs stock to add to your shortlist. USNA is a Zacks Rank of #2 (Buy) stock with a Value grade of A.
Shares of USANA Health Sciences are currently trading at a forward earnings multiple of 10.25 and a PEG ratio of 0.85 compared to its industry's P/E and PEG ratios of 41.97 and 1.96, respectively.
Over the last 12 months, USNA's P/E has been as high as 17.00, as low as 7.83, with a median of 11.15, and its PEG ratio has been as high as 1.42, as low as 0.65, with a median of 0.93.
USANA Health Sciences sports a P/B ratio of 1.10 as well; this compares to its industry's price-to-book ratio of 1.64. In the past 52 weeks, USNA's P/B has been as high as 1.66, as low as 0.83, with a median of 1.22.
These are just a handful of the figures considered in Rigel Pharmaceuticals and USANA Health Sciences's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that RIGL and USNA is an impressive value stock right now.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now?
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
One stock to keep an eye on is Rigel Pharmaceuticals (RIGL - Free Report) . RIGL is currently holding a Zacks Rank #2 (Buy) and a Value grade of A.
Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. RIGL has a P/S ratio of 1.75. This compares to its industry's average P/S of 3.73.
Finally, we should also recognize that RIGL has a P/CF ratio of 9.33. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. RIGL's P/CF compares to its industry's average P/CF of 12.83. Over the past year, RIGL's P/CF has been as high as 96.38 and as low as -21.56, with a median of 10.07.
USANA Health Sciences (USNA - Free Report) may be another strong Medical - Drugs stock to add to your shortlist. USNA is a Zacks Rank of #2 (Buy) stock with a Value grade of A.
Shares of USANA Health Sciences are currently trading at a forward earnings multiple of 10.25 and a PEG ratio of 0.85 compared to its industry's P/E and PEG ratios of 41.97 and 1.96, respectively.
Over the last 12 months, USNA's P/E has been as high as 17.00, as low as 7.83, with a median of 11.15, and its PEG ratio has been as high as 1.42, as low as 0.65, with a median of 0.93.
USANA Health Sciences sports a P/B ratio of 1.10 as well; this compares to its industry's price-to-book ratio of 1.64. In the past 52 weeks, USNA's P/B has been as high as 1.66, as low as 0.83, with a median of 1.22.
These are just a handful of the figures considered in Rigel Pharmaceuticals and USANA Health Sciences's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that RIGL and USNA is an impressive value stock right now.